Volume | 1,796,232 |
|
|||||
News | - | ||||||
Day High | 18.11 | Low High |
|||||
Day Low | 17.34 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Guardant Health Inc | GH | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
17.72 | 17.34 | 18.11 | 18.10 | 17.34 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
21,222 | 1,796,232 | $ 17.83 | $ 32,020,981 | - | 15.81 - 41.06 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:13:19 | 1 | $ 18.28 | USD |
Guardant Health (GH) Options Flow Summary
Guardant Health Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.2B | 121.71M | - | 563.95M | -479.45M | -3.94 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Guardant Health News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GH Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 16.23 | 18.27 | 15.81 | 16.84 | 1,745,491 | 2.07 | 12.75% |
1 Month | 17.80 | 22.57 | 15.81 | 18.68 | 2,533,582 | 0.50 | 2.81% |
3 Months | 22.26 | 23.36 | 15.81 | 19.41 | 2,015,607 | -3.96 | -17.79% |
6 Months | 25.89 | 30.36 | 15.81 | 22.20 | 1,810,875 | -7.59 | -29.32% |
1 Year | 24.47 | 41.06 | 15.81 | 27.21 | 1,855,444 | -6.17 | -25.21% |
3 Years | 159.92 | 169.425 | 15.81 | 47.46 | 1,455,788 | -141.62 | -88.56% |
5 Years | 67.64 | 181.07 | 15.81 | 63.11 | 1,290,144 | -49.34 | -72.95% |
Guardant Health Description
Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%. |